Severe colitis in patients with melanoma treated with BRAF/MEK inhibitors
Alimentary Pharmacology & Therapeutics2022Vol. 57(7), pp. 792–799
Citations Over Time
Franck Carbonnel, Émilie Routier, Thierry Lazure, Charlotte Mussini, Christophe Bellanger, Carine Merklen, Bakhtiar Bejou, Anthony Buisson, Aurélien Amiot, Antoine Meyer, Catherine Dong, Caroline Robert
Abstract
BRAF/MEK inhibitors can induce severe colitis characterised by ulcerations of the right colon.
Related Papers
- → Trametinib: a MEK inhibitor for management of metastatic melanoma(2015)177 cited
- → Trametinib in the treatment of melanoma(2015)39 cited
- → Dabrafenib–trametinib combination therapy re-challenge in advanced BRAFV600E-mutant non–small-cell lung cancer(2020)12 cited
- → BRAF and MEK Inhibitors Approved for Melanoma(2013)1 cited
- → The MEK inhibitor trametinib for the treatment of advanced melanoma(2014)